Page 979 - Read Online

Page 12 of 12 Lonardo et al. Hepatoma Res 2020;6:83 I http://dx.doi.org/10.20517/2394-5079.2020.89

65. Villa E, Camellini L, Dugani A, et al. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular
carcinoma. Cancer Res 1995;55:498-500.
66. Jonas S, Bechstein WO, Heinze T, et al. Female sex hormone receptor status in advanced hepatocellular carcinoma and outcome after
surgical resection. Surgery 1997;121:456-61.
67. Chow PK, Tai BC, Tan CK, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized
controlled trial. Hepatology 2002;36:1221-6.
68. Barbare JC, Bouche O, Bonnetain F, et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol
2005;23:4338-46.
69. Villa E, Dugani A, Fantoni E, et al. Type of estrogen receptor determines response to antiestrogen therapy. Cancer Res 1996;56:3883-5.
70. Wu Y, Yao N, Feng Y, et al. Identification and characterization of sexual dimorphismlinked gene expression profile in hepatocellular
carcinoma. Oncol Rep 2019;42:937-52.
71. Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors’ status in the tumour is the
strongest prognostic factor for survival. Hepatology 2000;32:233-8.
72. Natri HM, Wilson MA, Buetow KH. Distinct molecular etiologies of male and female hepatocellular carcinoma. BMC Cancer
2019;19:951.
73. Li CH, Haider S, Shiah YJ, et al. Sex differences in cancer driver genes and biomarkers. Cancer Res 2018;78:5527-37.